He & She MD

What He & She MD prescribes, by goal

Each “From” figure is the seller’s own starting price, in the unit the seller states. Where a required fee or a package length changes what one month costs, the smaller line under it is our arithmetic, not a figure the seller prints. Compounded preparations are not FDA-approved.

What it claims, and what it cites

The compounding position is stated. Medication is described as compounded by a US-licensed pharmacy partner. The pharmacies behind that are named, which is rare. One badge overstates what the FAQ gets right. Product pages carry the line FDA-regulated pharmacies. The FAQ answers the same question more carefully. It says FDA-registered instead. It adds that state boards inspect every six to twelve months. It adds that sterile batches undergo third-party testing. Registered and regulated are not the same word. The FAQ is the accurate one. The sermorelin page uses footnote markers that lead nowhere. Two numbers sit beside a claim that growth hormone falls up to 15% a decade. Another sits beside a claim of a 45% drop between thirty and sixty. There is no reference list on the page. There is no source link on the page either. Two outcome figures carry no method. One says 90% saw noticeable results by their second check-in. Another says 250,000 Americans have been treated. Neither states a sample or a date. The hedging changes between pages. The NAD+ product page says supports and may help. The NAD+ plans page says protect and repair DNA. It also says reduce inflammation and increase energy. The careful wording is on the page a search reaches. The bare wording is on the page a buyer checks out from. MOTS-c is the one to look at hardest. Its page offers treatment at $149 a month on a six-month plan. It describes the same prescribe-and-ship flow as every other product. MOTS-c appears on no FDA bulk-substance list. There is no 503A or 503B route for it.

Sold by He & She MD, not listed here

MOTS-c

On no 503A list (not in Categories 1–3 of the May 14, 2026 update). The FDA's compounding advisory committee voted 7–5 (two abstentions) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking.

The list of states served

The terms of service say the service is available only to people located in certain states. No list of those states is published anywhere on the site.

A phone number for canceling

The cancellation clause in the live terms reads "calling us at [INSERT CUSTOMER SERVICE PHONE]". The unfilled placeholder appears three times in that document.

MOTS-c as a priced row

On no 503A list (not in Categories 1–3 of the May 14, 2026 update). The FDA's compounding advisory committee voted 7–5 (two abstentions) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking.

Other sellers for weight

• 50 Stars Health

  Also prescribes Semaglutide, Tirzepatide.

  Visit 50 Stars Health →Read the 50 Stars Health review

• Actin

  Also prescribes Semaglutide, Tirzepatide.

  Visit Actin →Read the Actin review

• AgelessRx

  Also prescribes Semaglutide, Tirzepatide.

  Visit AgelessRx →Read the AgelessRx review